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Objective. Genetic predisposition to ovarian cancer is well documented. With the advent of next generation
sequencing, hereditary panel testing provides an efﬁcient method for evaluating multiple genes simultaneously.
Therefore, we sought to investigate the contribution of 19 genes identiﬁed in the literature as increasing the
risk of hereditary breast and ovarian cancer (HBOC) in a BRCA1 and BRCA2 negative population of patients
with a personal history of breast and/or ovarian cancer by means of a hereditary cancer panel.
Methods. Subjects were referred for multi-gene panel testing between February 2012 and March 2014.
Clinical data was ascertained from requisition forms. The incidence of pathogenic mutations (including likely
pathogenic), and variant of unknown signiﬁcance were then calculated for each gene and/or patient cohort.
Results. In this cohort of 911 subjects, panel testing identiﬁed 67mutations.With 7.4% of subjects harboring a
mutation on this multi-gene panel, the diagnostic yield was increased, compared to testing for BRCA1 and BRCA2
mutations alone. In the ovarian cancer probands, the most frequently mutated genes were BRIP1 (n= 8; 1.72%)
and MSH6 (n = 6; 1.29%). In the breast cancer probands, mutations were most commonly observed in CHEK2
(n = 9; 2.54%), ATM (n = 3; 0.85%), and TP53 (n = 3; 0.85%).
Conclusions.Although further studies are needed to clarify the exactmanagement of patients with amutation
in each gene, this study highlights information that can be captured with panel testing and provides support for
incorporation of panel testing into clinical practice.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionOvarian carcinoma is notable for a lack of effective screening,
ambiguous symptoms, and highestmortality among gynecologicmalig-
nancies. The late-stages of presentation have hampered modern efforts
to improve morbidity and mortality associated with this disease [1,2].
However, insight into genetic susceptibility for ovarian cancerand Gynecology, University of
f Medicine at Dignity Health
as Road, Suite 600, Phoenix, AZ
. This is an open access article underhas revolutionized care by providing an opportunity for risk-reducing
surgery in women with a known predisposition to disease [3,4].
Familial ovarian carcinoma has been described in the context of a
hereditary breast and ovarian cancer (HBOC) syndrome. Inherited in
an autosomal dominant fashion, HBOC is characterized by a young age
of onset, multiple primaries, bilateral breast cancer, and family history
of 1st- or 2nd-degree kin with similar diagnoses [5]. Current estimates
predict the incidence of ovarian and breast carcinoma in United States
to be 21,980 and 232,670, respectively [6]. Of these ovarian cases,
about 20–25% are thought to be a result of a hereditary predisposition,
while 5–7% of breast carcinoma is thought to be hereditary [7,8]. Histor-
ically, known genetic causes of HBOC have largely been explained by
germline mutations in the BRCA1 and BRCA2 (BRCA1/2) genes, with an
estimated risk of ovarian carcinoma from 30–62% in individuals withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1




Ashkenazi Jewish 54 5.93
Hispanic 24 2.63
African American/Black 18 1.98
Mixed Ethnicity 17 1.87
Asian 15 1.65
Middle Eastern 5 0.55
Total 911 100
87L.E. Minion et al. / Gynecologic Oncology 137 (2015) 86–92mutations [9–12]. A small contribution of hereditary ovarian carcinoma
risk has also been attributed toMLH1,MSH2,MSH6, and PMS2, the mis-
match repair (MMR) or Lynch genes [13,14].
Literature supports that BRCA1/2 genes are responsible for the major-
ity of known cause of HBOC and MMR genes are responsible for an addi-
tional proportion of hereditary ovarian cancer, while the remaining
hereditary risks are accounted for by several other genes as well as pro-
portion that is as yet unexplained [15]. Through the understanding of
other genetic hereditary syndromes (including Li–Fraumeni, Cowden,
and Peutz–Jegher syndromes), and homologous recombination (HR)
pathway genes, in which BRCA1/2 interact, several additional genes con-
tributing to the HBOC phenotype have been identiﬁed andwell described
in the literature [13–33]. Historically, testingmany genes for a single pro-
band has been laborious and cost prohibitive. Thus, testingwas common-
ly restricted to more commonly mutated genes that best ﬁt the patient's
clinical history. However, the advent of next generation sequencing tech-
nology hasmade it possible for clinicians to order a single test, evaluating
multiple genes simultaneously, in a cost effective and time efﬁcient fash-
ion, enabling a more complete genetic evaluation. Such testing has been
clinically available since 2012; however, limited literature exists assessing
the value of multi-gene panel testing in cohorts of patients with breast
and/or ovarian carcinoma. Therefore, we sought to investigate the con-
tribution of 19 genes identiﬁed in the literature as increasing the risk
of hereditary breast and/or ovarian cancer in a BRCA1/2 negative popu-
lation of patientswith a personal history of breast and/or ovarian cancer
by means of a next generation sequencing panel.
Materials & methods
Participants
Subjects were referred for multi-gene panel testing with OvaNext
(Ambry Genetics, Aliso Viejo, CA) between February 2012 and March
2014. For this retrospective cohort study, all identifying information
was removed from the database and the subjects were assigned codes.
This study was conducted in accordance with all regulations set for by
the Institutional Review Board of Dignity Health at St. Joseph's Hospital
and Medical Center, Phoenix, AZ. Inclusion criteria included: personal
history of breast and/or ovarian, fallopian, or primary peritoneal cancer.
Exclusion criteria included: male gender or mutation(s) or likely patho-
genic variant(s) identiﬁed in BRCA1/2 gene(s). From test requisition
forms self-identiﬁed demographic data, and self-identiﬁed personal
and family histories of cancer were extracted.
Genetic panel
The following 21 genes were analyzed and included for all subjects:
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM,MLH1,MRE11A,
MSH2,MSH6,MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, STK11,
and TP53 [13–33].
Mutation identiﬁcation and analysis
Genetic testing was completed in Ambry's laboratory using the
following protocol. Genomic deoxyribonucleic acid was isolated from
subject's whole blood or saliva samples using the QIAsymphony instru-
ment (Qiagen, Valencia, CA) according to manufacturer's protocols.
Deoxyribonucleic acid was quantiﬁed using a spectrophotometer
(Nanodrop, Thermoscientiﬁc, Pittsburgh, PA or Inﬁnite F200, TECAN,
San Jose, CA). Genomic deoxyribonucleic acid was then combined with
primer pairs in micro-droplets designed to the speciﬁed targets for
each gene to complete sequence enrichment (Raindance Thunderstorm
Technologies, Billerica, MA). Using Illumina HiSeq technology (Illumina,
San Diego, CA) enriched libraries were applied to the solid surface ﬂow
cell for clonal ampliﬁcation and sequencing. Sanger sequencingwas per-
formed for any region with insufﬁcient depth of coverage, deﬁned as50×. Additionally, bi-directional Sanger sequencing was performed to
conﬁrm all variant calls, other than known previously deﬁned benign
and likely benign alterations. To detect large deletions and duplications,
a targeted chromosomal microarray with increased probe density in
regions of interest was completed (Aglient, Santa Clara, CA).
Initial data processing and base calling, including extraction of
cluster intensities, was done using RTA 1.12.4 (HiSeq Control Software
1.4.5). Sequence quality ﬁltering was executed with the Illumina
CASAVA software (ver 1.8.2 Illumina, Hayward, CA). Sequence fragments
were aligned to the reference human genome (GRCh37) and variant
calls were generated using CASAVA. A minimum quality threshold of
Q30 was applied which translates to an accuracy of N99.9% for called
bases and mean coverage was N300×.
Annotated variants were then analyzed to determine the likelihood
of pathogenicity and classiﬁed into ﬁve tiers based on the recommenda-
tions of the American College of Medical Genetics and Genomics [34].
Alterations were classiﬁed in the following categories: pathogenic
mutation, variant likely pathogenic, variant of unknown signiﬁcance
(VUS), variant likely benign, and benign based on a previously described
multifactorial algorithm [35].
Data analysis
The incidence of pathogenicmutations (including likely pathogenic),
and VUSwere then calculated for each gene. The incidence of mutations
and VUS were compared across cohorts based on demographic and
clinical history information.
Genes were grouped in four categories: HR pathway/moderately
penetrant (ATM, BARD1, CHEK2,MRE11A, NBN, PALB2, RAD50, RAD51C),
Lynch syndrome genes (MLH1,MSH2,MSH6, PMS2, EPCAM), other high-
ly penetrant (CDH1, PTEN, STK11, TP53), and other moderate risk
(MUTYH). Monoallelic MUTYH mutation carriers were not included in
the mutation positive cohort.
Results
A total of 1187 subjects were referred for multi-gene testing.
After applying exclusion criteria the cohort included 911 subjects. The
following subjects were excluded from data analysis: 10 males, 26
females with an identiﬁed BRCA1/2 mutation and 240 females without
a personal history of breast or ovarian cancer. Demographic details for
the 911 subjects are provided in Table 1. There were a total of 466
subjects with a personal history of ovarian cancer, 353 subjects had a
personal history of breast cancer, and 92 had personal histories of
both breast and ovarian cancer.
Mutations identiﬁed in this cohort
Of the 911 subjects negative for a BRCA1/2mutation, 7.4% (n = 67)
had a pathogenic or likely pathogenic mutation (collectively referred to
asmutation herein) in a gene other than BRCA1/2 (Table 3, Fig. 1). Thirty
subjects (6.44%) with ovarian cancer had a mutation, 26 (7.37%) sub-
jects with breast cancer had a mutation, and 11 (11.96%) subjects
Table 2
Subject age at time of malignancy diagnoses.

























Breast cancer age at Dx Ovarian cancer age at Dx Breast cancer age at Dx Ovarian cancer age at Dx
Mean 48 52 55 53 55 55 57 55 55 58 57 57
Median 46 51 53 50 56 56 54 53 54 59 58 61
Age range 27–75 22–92 22–92 26–78 –85 17–85 45–75 36–76 28–76 41–72 27–87 26–87
Std dev 13.3 12.1 9.98 15.1 13.6 14 9.9 10.7 10.4 9.5 14.4 13.7
Age at Dx provided
(total N)
26 230 340 29 282 447 10 53 88 11 53 88
Dx = diagnosis, Std dev = standard deviation, Pos = positive mutation status, Neg = negative mutation status.
88 L.E. Minion et al. / Gynecologic Oncology 137 (2015) 86–92with both breast and ovarian cancer had a mutation. One individual
with ovarian cancer harbored both an ATM andMSH6mutation. One in-
dividual with breast cancer had 2 CHEK2 mutations. Mutations were
identiﬁed in all genes on the panel with the exceptions of MSH2 and
STK11 in this cohort.
In the ovarian cancer cohort (n = 466), among the HR pathway/
moderately penetrant genes, mutations were seen most frequently in
BRIP1 (n = 8; 1.71%), ATM (n = 4; 0.86%), and RAD51C (n = 3;
0.64%). Mutations were also identiﬁed in CHEK2 in 2 individuals and a
NBN, PALB2, RAD50, andMRE11Amutationwas identiﬁed in 1 individual
per gene. Among Lynch syndromes mismatch repair genes (MLH1,
MSH2,MSH6, PMS2, EPCAM), 8 mutations were identiﬁed (1.72% of the
cohort) withMSH6mutations being the most common, accounting for
75% (n = 6) of all Lynch mutations in the ovarian cancer only cohort.
Among the other highly penetrant genes, 2 individuals with ovarian
cancer had PTEN alterations while no alterations were identiﬁed in
TP53, CDH1, or STK11.Table 3













BRIP1 10 8 1 1
CHEK2 16 2 9 5b
ATM 7 4a 3 0
RAD51C 3 3 0 0
NBN 4 1 2 1
PALB2 4 1 2 1
RAD50 2 1 1 0
MRE11A 1 1 0 0
BARD1 2 0 2 0
Total 49 21 20 8
Lynch Genes
MSH6 10 6a 2 2
MLH1 2 2 0 0
PMS2 1 0 0 1
MSH2 0 0 0 0
Total 13 8a 2 3
Other Highly Penetrant
PTEN 2 2 0 0
TP53 3 0 3 0
CDH1 1 0 1 0
STK11 0 0 0 0
Total 6 2 4 0





16 9 4 3b
a 1 individual has both anMSH6 and ATMmutation.
b 1 individual has 2 CHEK2mutations and aMUTYHmutation, counted once in CHEK2
count.In the breast cancer only cohort (n=353), among the BRCApathway/
moderately penetrant genes, mutations were most commonly observed
in CHEK2 (n = 9; 2.55%), and ATM (n = 3; 0.85%). Interestingly, only 1
individual with breast cancer only carried a BRIP1mutation, despite the
high frequency of BRIP1mutations in the ovarian cancer only cohort.Mu-
tations were also identiﬁed in NBN (n= 2), PALB2 (n = 2), BARD1 (n =
2), and RAD50 (n=1). Of note, 2 individuals with breast cancer only had
a BARD1mutationwhile no individuals from the ovarian only cohort had
a BARD1mutation. Among Lynch syndromesmismatch repair genes only
2 mutations were identiﬁed in the breast only cohort, both of which
were inMSH6. Among the other highly penetrant genes, 3 individuals
with breast cancer had TP53 alterations and 1 had a CDH1 mutation,
while no alterations were identiﬁed in PTEN or STK11.
Among probands with breast and ovarian cancer, at least 1 in 7 of
those BRCA1/2 negative patients had a mutation in another breast and
ovarian cancer susceptibility gene. Eleven (11.96%) subjects in this
cohort had a mutation, including 5 with a mutation in CHEK2, 1 with a
BRIP1 mutation, 1 with a NBN mutation, 1 with a PALB2 mutation, 2
with aMSH6mutation, and 1 with a PMS2mutation.
Variants of unknown signiﬁcance
At least one VUS was identiﬁed in more than 1 in every 4 subjects
(259/911; 28.43%) (Fig. 2). This includes 12 individualswho also carried
a mutation. Thus, 12/67 (17.91%) of individuals with a positive test
result also carried at least one VUS. Of the 911 subjects, 43 carried two
or more VUS (4.72%), including 2 individuals with three VUS, and 1
individual with four VUS. When a VUS was present, the vast majority
(84.77%; 217/256) had just one VUS.
When considering ethnicity, VUS rates are highest among Middle
Eastern probands (80% with one or more VUS) followed by Asian
probands (53.3% with one or more VUS) and Black probands (44.4%
with one or more VUS). Rates of more than one VUS were highest
among Middle Easterners and Blacks (40.00% and 22.2% with two or
more VUS, respectively). VUS rates were lowest among Whites
(27.18%) and those with ethnicity unknown/not reported (22.22%).
Negative mutation ﬁndings and age of onset
Five hundred and eighty-six subjects (64.32%) did not have any
signiﬁcant or inconclusive genetic test results, including 237 probands
with breast cancer, 293 probands with ovarian cancer, and 56 probands
with breast and ovarian cancer. The age of onset among subjects negative
for a reportable ﬁnding was slightly older compared to those with a mu-
tation, though there was no signiﬁcant difference in age of onset among
any of the subgroups. In the breast cancer only cohort, the average age
of diagnosis amongnegative probandswas52 compared to 48 for positive
probands (p=0.07). In the ovarian cancer only cohort the average age of
ovarian cancer diagnosiswas 55 among negative probands and 53 among




Fig. 1.Mutation distribution: A. Full Cohort, B. Ovarian Cohort, C. Breast and Ovarian Cohort, and D. Breast Cohort.
89L.E. Minion et al. / Gynecologic Oncology 137 (2015) 86–92however, age of onset was slightly older among positive individuals com-
pared to those negative for a mutation, though the total number of sub-
jects available to compare in this group is small (p = 0.72 for breast
cancer age of onset, p = 0.97 for ovarian cancer age of onset) (Table 2).
Family history
Consistent across all cohorts, N90% of probands reported at least one
relative with cancer, with 93% of negative probands reporting a family
history of cancer, and98% of positive probands reporting a family history
of cancer in at least one relative (p=0.19). Among these relatives, 77.5%Fig. 2. Variants of unknown signiﬁcance (of positive probands reported cancer of any kind in at least one 1st
degree relative, and 72.7% of negative probands reported cancer in at
least one 1st- degree relative. Thus, the vast majority of individuals
with breast or ovarian cancer referred for OvaNext testing had a family
history of cancer, themajority of which included cancer in a 1st- degree
relative (Table 4A).
Resultswere analyzedmore speciﬁcally regarding breast and ovarian
cancer history among 1st and 2nd-degree relatives. Probands positive
for a pathogenic alteration and those negative for a reportable ﬁnding
were compared, subdividing by the probands' histories of breast and
ovarian cancer, breast cancer only, or ovarian cancer only (Table 4B).VUS) percentage observed by gene.
Table 4A






n % n %
1 or more 1st degree relative with cancer 54 80.6 426 72.8
1 or more relative affected with cancer 65 97.0 542 92.6
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Using a hereditary cancer multi-gene panel, we evaluated the contri-
bution of 19 additional genes that increase susceptibility to ovarian can-
cer amongwomennegative forBRCA1/2, with a personal history of breast
or ovarian cancer [20]. This yielded the identiﬁcation of 67 additional
mutations not in BRCA1/2. With 7.4% of patients harboring a mutation
on this multi-gene panel, this increases the diagnostic yield of genetic
testing substantially compared to testing for BRCA1/2mutations alone.
Themajority of mutations (72%) were identiﬁed in the HR pathway/
moderately penetrant breast and ovarian cancer genes in the HR path-
way. Remaining mutations were identiﬁed in Lynch syndrome genes
and other highly penetrant genes with established National Compre-
hensive Cancer Network or consortiummanagement guidelines.
The most commonmutations identiﬁed in subjects with ovarian can-
cer were in BRIP1 (n= 9). BRIP1, a member of the HR pathway, interacts
directly with BRCA1 and along with several other proteins creating a
macro-protein theorized to be involved in DNA repair during replication
[19,36]. Rafnar et al., found when evaluating an Icelandic HBOC popula-
tion that BRIP1 demonstrates tumor suppressive effects and mutations
in the gene increased risk of ovarian cancer with an odds ratio of 8.13.
The ﬁndings in this cohort of subjects conﬁrm reports of BRIP1 muta-
tions demonstrated in other series of patients with ovarian carcinoma
[15,30]. Reviewing family histories of probands with a BRIP1mutation,
4 subjects (44.4%) had a family history of ovarian cancer in a 1st- or
2nd-degree relative, compared to 29.3% of ovarian cancer probands neg-
ative for a reportableﬁnding of a family history of ovarian cancer (Tables
4A and 4B). Proband and family history frequencies of ovarian cancer
among BRIP1 mutation carriers suggest that BRIP1 has a higher pene-
trance for ovarian cancer compared to other genes on this panel.
Verifying that deﬁciencies in HR pathway are central in ovarian
carcinogenesis, the ovarian cohort demonstrated mutations in other
HR genes including CHEK2, ATM, NBN, PALB2, RAD51C, RAD50, and
MRE11A (n = 29). In fact, the majority of mutations (71.43%) were
found in genes in this pathway.
In reviewing the MMR genes in subjects with a personal history of
ovarian or breast and ovarian carcinoma, an overall mutation frequency
of 1.97% (11/558)was observed. Thiswas evenhigher than the frequency
previously reported (0.5%) [15], with nearly 1 in 50 individuals with
ovarian carcinoma in this cohort harboring a mutation in an MMR
gene, although a selection bias may exist given that this cohort was
referred for multi-gene panel testing that included MMR genes.
Furthermore, seven family histories did not meet Amsterdam II or
Bethesda criteria for Lynch syndrome testing, yet the proband didTable 4B
Family histories: Subjects that report a family history of malignancy and history of affected ﬁrs




1 or more relative with ovarian cancer 12 29.3
1 or more relative with breast cancer 14 34.1
1 or more relative with breast cancer at age b50 6 14.6harbor amutation in aMMRgene. These criteria have proven ineffective
with gynecologic malignancy, and some patients with MMR mutation
may be missed if genetic testing for MMR genes is limited to those
individuals who meet an established set of criteria for Lynch syndrome
genetic testing. These results suggest that expansion of Lynch syndrome
testing criteria should be considered, particularly for probands and
families presenting predominantly with ovarian cancer.
Interestingly, an additional 10 patients that did meet Amsterdam II
or Bethesda criteria did not harbor a MMR mutation, but in fact had
a mutation in another gene on this hereditary cancer panel with muta-
tions found in: CHEK2, MRE11A, BRIP1, RAD51C, and (monoallelic)
MUTYH. The personal and family histories among these additional
cases did not contain additional features that would be indicative of a
hereditary breast and ovarian cancer susceptibility, which may have
led a clinician to consider additional testing for these genes.
These ﬁndings demonstrated that MMR genes are implicated in a
small fraction of ovarian carcinoma and nearly 1 in 50 referred for a
hereditary cancer panel genetic testing. However phenotypic assess-
ment alone does not accurately guide a clinician in orderinggene speciﬁc
testing, and in some cases testing of additional genes may be warranted
evenwhen a familymeets clinical criteria for Lynch syndrome. Thus, this
data suggests that simultaneous testingwithmulti-genepanels provides
an efﬁcient means of evaluatingMMR and other ovarian carcinoma sus-
ceptibility genes.
Several individuals with breast cancer only in our cohort also had a
mutation in anMMRgene (n=2), however only one familymet criteria
for Lynch testing. A proband not meeting criteria had invasive ductal
carcinoma diagnosed at age 49 with no suggestion of Lynch syndrome,
such as family member with endometrial or colorectal cancer, reported
in her family history. There is conﬂicting evidence regarding the risk for
breast cancer in individuals with MMR mutations, with results herein
contributing further to the perplexing question regarding breast cancer
susceptibility and Lynch syndrome. As more multi-gene panel testing is
performed clinically and in research settings, more clarity should sur-
face regarding the correlation between breast cancer risk and Lynch
syndrome.
In assessing themutations identiﬁed in other highly penetrant genes
with established management guidelines, interestingly 2 individuals
with ovarian cancer had a PTEN alteration, which are of interest as the
risk for ovarian carcinoma is not commonly associated with mutations
in PTEN. Mutations in TP53 and CDH1 were identiﬁed in breast cancer
probands only, which is consistent with established predispositions
for these genes, and no alterationswere identiﬁed in STK11 in the entire
cohort. This trend has been observed in other panel testing as well,
wheremutations in STK11 have been limited to individuals with clinical
features suggestive of Peutz–Jegher syndrome, which is in contrast to
mutations in TP53, CDH1, and PTEN [39]. Data has been emerging in
these latter genes (TP53, CDH1, PTEN) suggesting that, much like Lynch
ﬁndings in this cohort, individuals with mutations identiﬁed on multi-
gene panel testing in these genes do not necessarily have expected
clinical features of the related genetic syndrome.
While panel testing is more likely to provide a more complete
capture of an individual's genetic landscape, there are several unan-
swered questions and areas of future research. As the number of genes
tested increases, the likelihood of detecting VUS increases as well.t-degree or second-degree family member.







N % N % N %
71 20.4 9 24.3 96 32.8
146 42.0 21 56.8 191 65.2
45 12.9 6 16.2 104 35.5
91L.E. Minion et al. / Gynecologic Oncology 137 (2015) 86–92Although these results are not negative per se, data is lacking as to the
clinical impact. These results may be confusing and unsettling to
patients as the implications to the proband and her family remains
unclear. Furthermore, if individuals underwent testing based on family
history alone, without a personal history of breast or ovarian cancer, it
remains to be clariﬁedwhether risk-reduction surgery would be appro-
priate for patients with mutations in all genes on the panel. Data is
needed regarding incidence, penetrance, and age-adjusted risks to
determine these practice guidelines. To quantify these important
measures that will steer practice guidelines, particularly given the rarity
of pathogenic mutations in many of these genes, large-scale data
sharing between laboratories, clinicians, and researchers is imperative.
Until this information is discovered on a population level, clinicians
and patients alike will be faced with positive results lacking established
management. Both parties maybe prompted to proceed with unneces-
sary additional evaluation (for example pelvic ultrasound and CA-125
screening for ovarian cancer, and MRI for breast cancer), testing of
family members or unwarranted risk-reducing surgery. These steps
would add to patient concern and ﬁnancial cost. Further data will help
to support or refute the extent inwhich additional preventive screening
and management strategies are warranted for individuals with muta-
tions in moderate penetrance genes. Furthermore, it will provide clarity
regarding actual risks for family members considering testing for a
known pathogenic mutation identiﬁed in the proband.
Although further studies are needed to clarify management of each
mutation, this study highlights the information that can be captured
with panel testing and merits further review for incorporation in clinical
practice. Next generation sequencing is inarguably a cost-effective and
time-efﬁcient strategy for testing many genes simultaneously. As more
data emerges regarding penetrance and age-adjusted risks through na-
tionwide and international data sharing initiatives such as those led by
PROMPT (The Prospective Registry of MultiPlex Testing) and ENIGMA
(Evidence-based Network for the Interpretation of Germline Mutant Al-
leles), the long term impact on reduction in cost ofmedical care andmor-
bidity/mortality also can be assessed. Furthermore, age of onset of breast
or ovarian cancer, and family history of breast or ovarian cancer did not
vary signiﬁcantly among subjects positive for amutation and those with-
out any reportable ﬁndings. Thus, this data does not support the utility of
severity of family history or age of onset of cancer to refer HBOC patients
for multi-gene panel testing.
As these questions are being answered in future studies, a more
complete genetic understanding is providing opportunities for translation
and treatment planning. BRCAmutation carriers with ovarian carcinoma
are noted to have a better prognosis, and clinical response to platinum
therapy is providing patients and families with prognostic information
speciﬁc to their mutation. Moreover, targeted therapies are under-
development that exploit the defect in HR, inhibiting poly(ADP-ribose)-
polymerase (PARP), and creating a lethal submission of DNA repair by
interrupting base excision repair. BRCAmutations confer sensitivity to
PARP inhibitors and it has been suggested that this sensitivity may
extend to other FA-BRCA (HR) genes as well [37–40].
This population of probands was referred nationwide for testing,
making our data set large and generalizable to patient cohorts with a
history of breast or ovarian cancer. However, our study has several
limitations, including a potential selection bias as all subjects were
referred for genetic testing and not recruited at random. Additionally,
demographic and clinical history data was limited to reported informa-
tion on test requisition forms without direct review of patient medical
records. Therefore, personal and family histories could be incomplete,
or underreported for all affected family members.
Here we have evaluated the contribution of 19 genes in a BRCA1/2
negative population with a personal history of breast and/or ovarian
cancer. Multi-gene panels provide an efﬁcient means of capturing a
genetic diagnosis; this study highlights information that can be cap-
tured with panel testing and suggests a role for incorporation in clinical
practice.Conﬂict of interest statement
Dr. Elizabeth Chao, Jill Dolinsky, and Charles Dunlop are employed by Ambry Genetics.
Drs. Bradley Monk, Dana Chase and Lindsey Minion have nothing to disclose.Acknowledgment
The authors would like to thank Daniele A. Sumner, BA for her
assistance in editing the manuscript. The authors would also like to
thank Madison Brawer for her assistance in compiling this data, and
would like to thank all referring clinicians who contributed valuable
clinical histories on patients referred for testing. The authors are solely
responsible for the content and preparation.References
[1] Siegel R, Naishadham N, Jemal A. Cancer statistics, 2013. CA Cancer J Clin Jan 2013;
63(1):11–30.
[2] Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of
advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol Apr 2013;10(4):
211–24.
[3] Kauff ND, Satagopan JM, Robson ME, Scheuler L, Hensley M, Clifford AH, et al. Risk-
reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N
Engl J Med May 23 2002;346(21):1609–15.
[4] Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates
associated with risk-reduction salpingo-oophorectomy in BRCA1 or BRCA2mutation
carriers. J Natl Cancer Inst Jan 21 2009;101(2):80–7.
[5] Nelson HD, Huffman LH, Fu R, Harris EL, U.S. Preventive Task Force. Genetic risk
assessment and BRCA mutation testing for breast and ovarian cancer susceptibility:
systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern
Med Sep 6 2005;143(5):362–79.
[6] American Cancer Society. Facts and Figs. http://www.cancer.org/acs/groups/
content/@research/documents/webcontent/acspc-042151.pdf; 2014.
[7] Weisman SW, Weiss SM, Newlin AC. Genetic testing by cancer site ovary. Cancer J
Jul–Aug 2012;18(4):320–7.
[8] Van der Groep P, Van derWall E, Van Diest PJ. Pathology of hereditary breast cancer.
Cell Oncol Apr 2011;34(2):71–88.
[9] Miki Y, Swensen J, Shattuck-Eidens D, Futreal A, Harshman K, Tavtigian S, et al. A
strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Science Oct 7 1994;266(5182):66–71.
[10] Wooster R, Bignell G, Lancaster J, Collins N, Gregory S, Gumbs C, et al. Identiﬁcation
of the breast cancer susceptibility gene BRCA2. Nature Dec 21–28 1995;378(6559):
789–92.
[11] National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology.
Genetic/familial High-Risk Assessment: Breast and Ovarian (version 4.2013).
http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.
(Accessed February 22,2014).
[12] Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risk
of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected
in case series unselected for family history: a combined analysis of 22 studies. Am
J Hum Genet May 2003;72(5):1117–30.
[13] Lu KH, Daniels M. Endometrial and ovarian cancer in womenwith Lynch syndrome:
update in screening and prevention. Fam Cancer Jun 2013;12(2):273–7.
[14] Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer
risk associated with germline DNA mismatch repair gene mutations. Hum Mol
Genet Jan 1997;6(1):105–10.
[15] Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12
genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identiﬁed by
massively parallel sequencing. Proc Natl Acad Sci U S A Nov 1 2011;108(44):
18032–7.
[16] Meindl A, Hellbrand K, Wiek C, Erven V, Wappenschmidt B, Niederacher D, et al.
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a
human cancer susceptibility gene. Nat Genet May 2010;42(5):410–4.
[17] Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS. Clinical
evaluation of multiple-gene sequencing panel for hereditary cancer risk assessment.
J Clin Oncol Jul 1 2014;32(19):2001–9.
[18] Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, et al.
Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet Oct 2 2011;43(11):
1104–7.
[19] Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, et al. Spectrum of
mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
JAMA Mar 22 2006;295(12):1379–88.
[20] Coulet F, Fajac A, Colas C, Eyries M, Dion-Miniere A, Rouzier R, et al. Germline
RAD51C mutations in ovarian cancer susceptibility. Clin Genet Apr 2013;83(4):
332–6.
[21] Damiola F, Pertesi M, Oliver J, Calvez-Kelm FL, Voegele C, Young EL, et al. Rare key
functional domain missense substitutions in MRE11A, RAD50, and NBN contribute
to breast cancer susceptibility: results from a Breast Cancer Family Registry case–
control mutation-screening study. Breast Cancer Res Jun 3 2014;16(3):R58.
[22] D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl
J Med May 20 2010;362(20):1909–19.
92 L.E. Minion et al. / Gynecologic Oncology 137 (2015) 86–92[23] Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, et al. Breast-
cancer risk in families with mutations in PALB2. N Engl J Med Aug 7 2014;371(6):
497–506.
[24] Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL. Screening for BRCA1,
BRCA2, CHEK2, PLAB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish
BRCA1/2-founder mutations-negative breast and/or ovarian cancer individuals.
Breast Cancer Res Feb 28 2011;13(1):R20.
[25] ThorstensonYR, Roxas A, Kroiss R, JenkinsMA, YuKM, Bachrich T, et al. Contributions
of ATM mutations to familial breast and ovarian cancer. Cancer Res Jun 15 2003;
63(12):3325–33.
[26] Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline
and somatic mutations in homologous recombination genes predict platinum
response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin
Cancer Res Feb 1 2014;20(3):764–75.
[27] Casadei S, Norquist BM, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, et al.
Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to
familial breast cancer. Cancer Res Mar 15 2011;71(6):2222–9.
[28] Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, et al.
RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet Aug 15 2011;
20(16):3278–88.
[29] Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects.
Gynecol Oncol Feb 2012;124(2):347–53.
[30] Baysal BE, DeLoia JA, Willett-Brozick JE, Goodman MT, Brady MF, Modugno F, et al.
Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol Oct 2004;
95(1):62–9.
[31] Castera L, Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O, et al. Next-
generation sequencing for the diagnosis of hereditary breast and ovarian cancer
using genomic capture targeting multiple candidate genes. Eur J Hum Genet Nov
2014;22(11):1305–13.[32] Kanchi KL, JohnsonKJ, Lu C,McLellanMD, LeisersonMDM,WendlMC, et al. Integrated
analysis of germline and somatic variants in ovarian cancer. Nat Commun2014;5:3156.
[33] D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer Jan
2003;3(1):23–34.
[34] Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, et al. ACMG
recommendations for standards for interpretation and reporting of sequence
variations: revisions 2007. Genet Med Apr 2008;10(4):294–300.
[35] LaDuca H, Stuenkel AJ, Dolinshky JS, Keiles SK, Tandy S, Pesaran T, et al. Utilization of
multigene panels in hereditary cancer predisposition testing: analysis of more than
2,000 patients. Genet Med Apr 2014;24.
[36] Tan DSP, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanely S, et al. “BRCA”
syndrome in ovarian cancer: a case–control study describing the clinical features
and outcome of patients with epithelial ovarian cancer associated with BRCA1 and
BRCA2 mutations. J Clin Oncol Dec 1 2008;26(34):5530–6.
[37] Pennington KP, Walsh T, Harrell M, et al. Germline and somatic mutations in homol-
ogous recombination genes predict platinum response and survival in ovarian,
fallopian tube and peritoneal carcinomas. Clin Cancer Res Feb 1 2014;20(3):764–75.
[38] Chong HK,Wang T, Lu HM, Seider S, Lu H, Keiles S, Chao EC, et al. The validation and
clinical implementation of BRCAplus: a comprehensive high-risk breast cancer
assay. PLoS One May 15 2014;9(5):e97408.
[39] Konstantinopoulos PA, Spentzos D, Karlan B, Taniguchi T, Founzilas E, Fancoeur N,
et al. Gene expression proﬁle of BRCAness that correlates with responsiveness to
chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin
Oncol Aug 1 2010;28(22):3555–61.
[40] Wysham WZ, Mhawech-Faucegila P, Li H, Hays L, Syriac S, Skrepnik T, et al.
BRCAness proﬁle of sporadic ovarian cancer predicts disease recurrence. PLoS One
2012;7(1):e30042.
